Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC

Part of paid clinical trials in Tucson, Arizona.

Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Study ID
NCT04242173
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cemiplimab-Rwlc — DRUG
    Cemiplimab-rwlc will be administered as a flat dose of 350 mg IV over approximately 30 minutes every 21 days (+/- 3 days)

Study Details

The purpose of this research study is to determine how people with weakened immune systems and unresectable (cannot be removed by surgery) locally recurrent and/or metastatic cutaneous squamous cell carcinoma (CSCC) respond to study treatment with Cemiplimab. Cemiplimab is approved for sale in United States by the U.S. Food and Drug Administration (FDA).

Key Dates

Start date
Jun 25, 2020
Status verified
Nov 2022
Primary completion
May 26, 2022
Completion
May 26, 2022

Study Design

Enrollment
3 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cemiplimab-rwlc treatment
    Immunocompromised patients will be given Cemiplimab-rwlc every 3 weeks

Primary Outcome Measure

Overall Response Rate [ Time Frame: Up to 12 months ]

Locations (2)

FacilityCityStateZIPSite coordinators
University of Arizona Cancer CenterTucsonArizona85724-
Moffitt Cancer CenterTampaFlorida33612-

Find similar trials in Tucson, AZ

By condition
Skin cancer
By specialty
OncologySkin cancerDermatology
By research site
University of Arizona Cancer Center· Tucson, AZMoffitt Cancer Center· Tampa, FL

Related Studies